Findings showed treatment with Xhance was associated with a statistically significant improvement on both study endpoints compared with placebo. The Food and Drug Administration (FDA) has approved ...
LOS ANGELES (KABC) -- One in eight U.S. adults struggle to breathe and battle the persistent pain and discomfort of chronic sinusitis. Even with sprays, irrigations and pills, a staggering 80% of ...
Xhance (fluticasone propionate) is a prescription nasal spray. It’s used to treat nasal and sinus inflammation with or without nasal polyps in adults. This drug can interact with other medications, ...
ReOpen was the first ever large placebo-controlled clinical trial program to demonstrate statistically significant reduction of symptoms in chronic sinusitis patients without nasal polyps Clinical ...
YARDLEY, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Optinose (OPTN) (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved Xhance for the treatment of chronic rhinosinusitis without nasal polyps among patients aged 18 ...
The FDA expanded the approval of fluticasone propionate (Xhance) nasal spray for chronic rhinosinusitis to also include treatment of adults without nasal polyps, manufacturer Optinose announced on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results